--- OCR PAGE 39 ---
From: ‘Naus, Monika [BCCDC]

To: Henry, Bonnie HLTH:EX

Cec: Gustafson, Reka [BCCDC]

Subject: higher rates of anaphylaxis associated with one of the Pfizer lots

Date: March 11, 2021 7:26:13 PM

Attachments: — COVID19 AEFI Summary Report 2021-03-11.htm|

Hi Bonnie

As we just discussed, we notified the feds today that we have noted a higher rate of reported
anaphylaxis with one lot of the Pfizer vaccine. We asked them to take a look at the lot specific
anaphylaxis rates for the Pfizer vaccine to see whether this is being noted elsewhere in the country, or
whether we are the only place reporting high rates. We know that overall BC is reporting higher rates
of anaphylaxis - appreciably higher than US, where they reported 11 per million doses, and in asking
PHAC where we figure compared to the rest of the country,$.13
8.13

8.13

Here is the relevant information:

BC has received a total of 18 AEFI reports for events managed as anaphylaxis following a dose of the
Pfizer COVID-19 mRNA vaccine lot number EP6017. There were 44,850 doses of this lot distributed in
BC (shipped February 17), for a rate of anaphylaxis of 40 per 100,000 doses distributed. These events
constitute 33% of all anaphylaxis events reported following receipt of Pfizer mRNA vaccine in BC, for
which the overall anaphylaxis reporting rate has been 18.7 per 100,000. This lot accounts for about 12%
of Pfizer MRNA doses distributed in BC to date.

Ten of the anaphylaxis reports were assessed as meeting the Brighton Collaboration anaphylaxis case
definition levels 1, 2, or 3 criteria of diagnostic certainty (rate of 22 per 100,000 doses distributed).
Two individuals were admitted to hospital following the anaphylaxis event. 6.22 of the hospitalized
cases was hospitalized not because of anaphylaxis but because they received 3 doses of adrenaline and
had a cardiac event (not an MI, but arrythmia). Both recovered fully. There were also 13 other allergic
events reported for the same lot number, accounting for about 12% of allergic events following Pfizer
mRNA vaccine in BC (in line with this being 12% of Pfizer doses distributed); the lot-specific rate of
allergic events was somewhat lower than the overall provincial rate for this vaccine.

Reports were received from all BC health authorities. Fifteen of the individuals were female, and the
average age was 46 (range 23-68).

Today’s full daily report of our AEFI is enclosed (same as | sent you earlier today); the 18 AEFI reports
were reported by all regions and we will run the regional rates tomorrow to look if there was much off
at that level.

s.13

Thank you,

Monika

Monika Naus MD FRCPC

Medical Director, Communicable Diseases & Immunization Service

Medical Head, Immunization Programs & Vaccine Preventable Diseases

BC Centre for Disease Control

Page 39 of 40 HTH-2021-13807